Appearance of peanut agglutinin in the blood circulation after peanut ingestion promotes endothelial secretion of metastasis-promoting cytokines
暂无分享,去创建一个
C. Chen | J. Rhodes | D. Pritchard | C. Duckworth | Weikun Wang | Lu-Gang Yu | Chen Chen | Paulina Sindrewicz-Goral
[1] H. Janssen,et al. M2‐polarized tumor‐associated macrophages promote epithelial‐mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma , 2019, Journal of cellular biochemistry.
[2] G. Hoxhaj,et al. The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism , 2019, Nature Reviews Cancer.
[3] K. Mimori,et al. Potentials of C‐C motif chemokine 2–C‐C chemokine receptor type 2 blockers including propagermanium as anticancer agents , 2019, Cancer science.
[4] J. Maher,et al. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. , 2018, Biochemical Society transactions.
[5] J. Rhodes,et al. Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells , 2017, Cell Death and Differentiation.
[6] A. Egloff,et al. IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. , 2017, Oral oncology.
[7] Ting Zhang,et al. PRAS40 signaling in tumor , 2017, Oncotarget.
[8] R. Beynon,et al. Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells , 2017, The Journal of Biological Chemistry.
[9] Ø. Bruserud,et al. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells , 2016, Molecules.
[10] Stacey A. Kenfield,et al. Nut consumption and prostate cancer risk and mortality , 2016, British Journal of Cancer.
[11] A. Orekhov,et al. Endothelial PECAM-1 and its function in vascular physiology and atherogenic pathology. , 2016, Experimental and molecular pathology.
[12] I. Kato,et al. CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor , 2016, Oncogene.
[13] R. Muschel,et al. Targeting the CCL2-CCR2 signaling axis in cancer metastasis , 2016, Oncotarget.
[14] T. Zeng,et al. CCL2-CCR2 axis promotes metastasis of nasopharyngeal carcinoma by activating ERK1/2-MMP2/9 pathway , 2015, Oncotarget.
[15] Jane Y. Wu,et al. CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development , 2015, Cell Research.
[16] J. Rhodes,et al. Peanut agglutinin appearance in the blood circulation after peanut ingestion mimics the action of endogenous galectin-3 to promote metastasis by interaction with cancer-associated MUC1. , 2014, Carcinogenesis.
[17] S. K. Watkins,et al. Novel Regulation of CD80/CD86-induced Phosphatidylinositol 3-Kinase Signaling by NOTCH1 Protein in Interleukin-6 and Indoleamine 2,3-Dioxygenase Production by Dendritic Cells*♦ , 2014, The Journal of Biological Chemistry.
[18] W. Willett,et al. Association of nut consumption with total and cause-specific mortality. , 2013, The New England journal of medicine.
[19] Xiyun Yan,et al. CD146, a multi-functional molecule beyond adhesion. , 2013, Cancer letters.
[20] Y. Liu,et al. Monocyte Chemoattractant Protein-1/CCL2 Produced by Stromal Cells Promotes Lung Metastasis of 4T1 Murine Breast Cancer Cells , 2013, PloS one.
[21] C. Chen,et al. Increased Circulation of Galectin-3 in Cancer Induces Secretion of Metastasis-Promoting Cytokines from Blood Vascular Endothelium , 2013, Clinical Cancer Research.
[22] Dongling Yang,et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. , 2012, Blood.
[23] Lu-Gang Yu,et al. Galectin-3--a jack-of-all-trades in cancer. , 2011, Cancer letters.
[24] C. Chen,et al. Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium , 2011, Clinical Cancer Research.
[25] K. Pantel,et al. The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study , 2011, The Prostate.
[26] M. Wicha,et al. Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots , 2011, Clinical Cancer Research.
[27] J. Rhodes,et al. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis , 2010, Molecular Cancer.
[28] Y. DeClerck,et al. Interleukin-6 in bone metastasis and cancer progression. , 2010, European journal of cancer.
[29] Larry Norton,et al. Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.
[30] J. Rhodes,et al. Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. , 2009, Cancer research.
[31] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[32] T. Harris,et al. Regulation of Proline-rich Akt Substrate of 40 kDa (PRAS40) Function by Mammalian Target of Rapamycin Complex 1 (mTORC1)-mediated Phosphorylation* , 2008, Journal of Biological Chemistry.
[33] Lu-Gang Yu. The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression , 2007, Glycoconjugate Journal.
[34] J. Hirabayashi,et al. Galectin-3 Interaction with Thomsen-Friedenreich Disaccharide on Cancer-associated MUC1 Causes Increased Cancer Cell Endothelial Adhesion* , 2007, Journal of Biological Chemistry.
[35] Matthew J. Craig,et al. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases , 2007, Cancer and Metastasis Reviews.
[36] B. Rollins,et al. CCL2 (monocyte chemoattractant protein-1) and cancer. , 2004, Seminars in cancer biology.
[37] D. Jackson. The unfolding tale of PECAM‐1 , 2003, FEBS letters.
[38] Chia-Hung Chou,et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway , 2003, Oncogene.
[39] E. van Marck,et al. Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer , 2003, International journal of cancer.
[40] D. Ashby,et al. Diet and colorectal cancer: an investigation of the lectin/galactose hypothesis. , 2002, Gastroenterology.
[41] D R Alessi,et al. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? , 2001, Journal of cell science.
[42] J. Ward,et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. , 2000, Blood.
[43] I. Shih. The role of CD146 (Mel‐CAM) in biology and pathology , 1999, The Journal of pathology.
[44] J. Milton,et al. Identification of intact peanut lectin in peripheral venous blood , 1998, The Lancet.
[45] O. Vainio,et al. HEMCAM, an adhesion molecule expressed by c-kit+ hemopoietic progenitors , 1996, The Journal of cell biology.
[46] W. Muller,et al. Roles of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in natural killer cell transendothelial migration and beta 2 integrin activation. , 1996, Journal of immunology.
[47] J. Smith,et al. Peanut lectin: a mitogen for normal human colonic epithelium and human HT29 colorectal cancer cells. , 1992, Journal of the National Cancer Institute.
[48] J. Lehmann,et al. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[49] J. Rhodes,et al. Peanut lectin stimulates proliferation in colonic explants from patients with inflammatory bowel disease and colon polyps. , 1994, Gastroenterology.